The Cost of Not Retesting: Human Immunodeficiency Virus Misdiagnosis in the Antiretroviral Therapy "Test-and-Offer" Era
The Cost of Not Retesting: Human Immunodeficiency Virus Misdiagnosis in the Antiretroviral Therapy "Test-and-Offer" Era
复制标题
DOI：
10.1093/cid/cix341
复制
发表时间：
2017-08-01
影响因子：
11.8
通讯作者：
Gregson, Simon
中科院分区：
文献类型：
--
作者：
Eaton, Jeffrey W.;Johnson, Cheryl C.;Gregson, Simon
我们比较了人类免疫缺陷病毒(HIV)阳性者在开始抗逆转录病毒治疗(ART)前重新检测的估计成本与向被误诊的HIV阴性者提供ART的成本。避免不必要的抗逆转录病毒治疗费用所节省的费用比在1年内使用代表方案设置中艾滋病毒检测性能的假设的重新检测费用更大。各国应在启动ART之前进行重新测试。
We compared estimated costs of retesting human immunodeficiency virus (HIV)-positive persons before antiretroviral therapy (ART) initiation to the costs of ART provision to mis-diagnosed HIV-negative persons. Savings from averted unnecessary ART costs were greater than retesting costs within 1 year using assumptions representative of HIV testing performance in programmatic settings. Countries should implement re-testing before ART initiation.